Discovery and development of ML3000
- 1 May 2001
- journal article
- Published by Springer Nature in Inflammopharmacology
- Vol. 9 (1-2) , 101-112
- https://doi.org/10.1163/156856001300248371
Abstract
NSAID management of the inflammatory process has focused on reducing the production of inflammatory prostaglandins by inhibiting the cyclooxygenase (COX) enzyme. However, blocking COX also reduces gastroprotective prostaglandins, causing the well-known gastrointestinal side effects. Furthermore, a shunting of arachidonic acid to the 5-lipoxygenase (5-LOX) pathway may also occur, causing an increase in leukotrienes and further GI damage. Several compounds, designed to block both COX and 5-LOX, have failed in clinical trials due to liver toxicity, related to their redox potential. ML3000 is a new pyrrolizine compound resulting from a systematic approach to design a non-redox substrate analog of arachidonic acid that inhibited both COX and 5-LOX. Pharmacodynamic studies determined that ML3000 is a dual inhibitor of COX and 5-LOX, with analgesic, anti-inflammatory, antipyretic, antiplatelet, and anti-bronchoconstrictive activity, and minimal gastrointestinal side effects. Clinical studies show efficacy in osteoarthritis and excellent gastrointestinal safety. ML3000 is now in phase III development.Keywords
This publication has 13 references indexed in Scilit:
- The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenaseInflammopharmacology, 2001
- (6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-LipoxygenaseJournal of Medicinal Chemistry, 1994
- Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs.Gut, 1993
- Lung inflammatory cells after exposure to mouldy hayInflammation Research, 1993
- Synthesis and quantitative structure-activity relationships of diclofenac analogsJournal of Medicinal Chemistry, 1990
- Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationshipsJournal of Medicinal Chemistry, 1990
- Antioxidant-based inhibitors of leukotriene biosynthesis. The discovery of 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5-benzofuranol, a potent topical antiinflammatory agentJournal of Medicinal Chemistry, 1990
- Antiphlogistische 2,3 Dihydro-1H-pyrrolizine, 13. Mitt.: Stellungsisomere Diaryldihydropyrrolizinyl-essigsäuren und -hydroxyethyl-DerivateArchiv der Pharmazie, 1988
- Hydroxamic acid inhibitors of 5-lipoxygenaseJournal of Medicinal Chemistry, 1987
- Pharmacological Properties of a New Anti-Inflammatory Compound, α-(3,5-Di-Tert-Butyl-4-Hydroxybenzylidene)-γ-Butyrolactone (KME-4), and Its Inhibitory Effects on Prostaglandin Synthetase and 5-LipoxygenaseThe Japanese Journal of Pharmacology, 1984